STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-08-23
Here’s whether Relay Therapeutics, Inc. Common Stock (RLAY) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+6.65% over 10 days); RSI 59 — healthy momentum range; strong 1-year return of +470.1%; 3-month momentum positive (+43.7%). Currently 8.6% off its 52-week high. Score: +7/7.
RLAY is in a confirmed uptrend, trading above both its 50-day ($18.75) and 200-day ($12.33) moving averages. An RSI of 58.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +470.1% compares to +20.5% for SPY (beat the market by 449.6%).
$10,000 invested 1 year ago→ $57,009 today
vs. S&P 500 (SPY) — same period beat market by 449.6%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($12.33)
✓Above 50-day MA ($18.75)
✓RSI(14) neutral zone (30–70) — currently 58.7
✓Positive return (+470.1%)
✓Within 10% of period high (−8.6%)
Period Range $19.44
$3.31$21.27
RSI (14) 58.7
0 · OversoldOverbought · 100
Key Metrics
Price$19.44
Period Return+470.1%
Period High$21.27
Period Low$3.31
Drawdown−8.6%
MA-50$18.75
MA-200$12.33
RSI (14)58.7
Avg Volume (30d)2.2M
vs. SPYbeat by 449.6%
Return Rank#11 of 999
Trend Signals
Price is above the 200-day moving average ($12.33)